Other publication

Cost-Effectiveness of Pasireotide Long-Acting in a Treatment of Acromegaly in Finland. Economic Evaluation Based on Finnish Auria Biobank Data on Health Care Resource Utilization




AuthorsHahl J, Kurki S, Miettinen T, Snicker K

Publication year2015

JournalValue in Health

Volume18

Issue7

First page A609

Number of pages1

ISSN1098-3015

DOIhttps://doi.org/10.1016/j.jval.2015.09.2109


Abstract

The objective is to describe disease progression and treatment patterns of acromegaly in patients with inadequate biochemical control, assess how biochemical control will impact disease progression and treatment pathways and estimate the economic efficiency of pasireotide long-acting (PASI) in a treatment of acromegaly in Finland. PASI is compared to pegvisomant + somatostatin analoque (PEG+SSA) in patients with inadequately controlled acromegaly.




Last updated on 2024-26-11 at 19:58